Hypera Strikes Takeda Deal To Dominate Brazil's OTC Market
Brazil's Hypera is paying Takeda $0.8bn for a portfolio of brands which will make it the "undisputed leader" in the South American country's OTC market.
You may also be interested in...
Genomma Lab reports OTC sales rise in Q1 thanks to gains in its LATAM region, while Brazil's Hypera posts big jump in turnover due to acquisitions.
HBW Insight reveals the biggest consumer health deals of 2020, and identifies growing private equity investment, portfolio streamlining by major players and pharma firms exiting OTC as the major drivers of M&A activity.
Takeda will divest a portfolio containing OTC drugs and dietary supplements to Denmark's Orifarm, while rumors suggest the company is poised to offload its substantial Japanese consumer healthcare business.